盤中異動 | 藥明生物盤中上漲5%,報於59.85港元
2022年6月6日9時50分,藥明生物(HK02269)盤中上漲5%,報於59.85港元,成交額達1.94億港元,換手率達到0.05%。
6月6日訊,6月6日藥明生物微信公衆號消息,公司宣佈位於江蘇省無錫市的全新生物製劑五廠(DP5)已正式投入GMP生產。這也是藥明生物在全球範圍內投產的第九個生物製劑廠。DP5應用了先進的隔離器灌裝生產線,能夠爲1mL細長、1mL、2.25mL、3mL等不同規格的預充針提供連續穩定的製劑灌裝服務。製劑灌裝速度最快可達400支/分鐘,年產能高達1700萬支。與傳統的製劑灌裝生產線相比,DP5可顯著降低污染風險,有效滿足無菌灌裝的環境要求。
5月24日,瑞銀:維持藥明生物(02269)“買入”評級,目標價110.67港元。4月14日,廣發證券:予藥明生物(02269)“買入”評級,目標價101.11港元。
最新的財務數據顯示,公司於2021年4季度,營業收入102.9億人民幣,淨利潤35.09億人民幣;營業收入同比增加83.35%,毛利潤同比增加90.05%,淨利潤同比增加107.28%。
盈立趨勢長盈模型最近一次交易信號,2022年6月2日出現關注信號,觸發價格爲57.0港元(信號僅供參考)。
uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.